Savara posts corporate presentation on autoimmune PAP, highlights MOLBREEVI Phase 3 data

• Savara highlighted Phase 3 IMPALA-2 data for MOLBREEVI (molgramostim inhalation solution) in autoimmune pulmonary alveolar proteinosis, a rare lung disease with no approved drugs in US or Europe.
• Primary endpoint met, with change from baseline in DLCO% at Week 24 showing a 6.00 least-squares mean difference versus placebo (p=0.0007); Week 48 DLCO% difference was 6.90 (p=0.0008).
• Quality-of-life improved on St. George’s Respiratory Questionnaire total score at Week 24, with a -6.59 between-group difference (p=0.0072); Week 48 difference was -4.87 (p=0.1046).
• Trial completion remained high, with 97.5% of MOLBREEVI patients and 96.4% of placebo patients completing Week 48; treatment discontinuations in double-blind period were 3%.
• BLA PDUFA date set for Nov. 22, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.